Success Story: Large Pharmaceutical Company
In their words
Working with the i3 allowed us to avoid many pitfalls and significantly shortened the time needed to develop new imaging agents we needed to test novel therapeutic drugs.
Could we develop a non-invasive means to monitor the efficacy of a new therapeutic drug in living animals?
How we helped
The i3 guided the design of the studies and advised on the synthesis and labeling strategies for novel positron emission tomography (PET) imaging agents used to evaluate the drug.
We synthesized novel PET imaging probes and validated the probes in a variety of animal models. Using the new PET imaging probes, we verified that the therapeutic drug was efficacious in a mouse model of myocardial infarction (heart attack).
Next big step
Our collaboration proved the efficacy of the therapeutic drug and clinical trials are being planned. A patent had been filed on the PET probes, and an investigational new drug (IND) application is being planned for the PET probe.